Home

In real-world studies, the t:slim X2 insulin pump demonstrated:

Immediate Improvements

Users demonstrated an immediate 10% time in range increase resulting in 2.4 more hours per day spent in range compared to prior therapy and sustained over 12 months.¹

Decrease in Burden

Users experienced a 42% reduction in diabetes impact and meaningful improvements in quality of life including trust in the system and greater BG control.²

More Control Overnight

Users experienced a 90% time in range between the hours of 4 am and 7 am while using Control-IQ technology with a Tandem insulin pump.¹

t:slim X2 Insulin Pump

With a colour touchscreen and sleek design, the t:slim X2 insulin pump is the proven system that holds up to 300 units of insulin. This sophisticated, modern device integrates with Dexcom G6 and Dexcom G7 sensors^* and offers infusion set options that are designed to fit any lifestyle.

Explore Features

Control-IQ technology makes diabetes management easier by using CGM values to predict glucose levels 30 minutes ahead.

See How It Works

Helps Prevent Lows

The t:slim X2 pump with Control-IQ technology decreases or stops basal insulin if sensor glucose is predicted to be low.

Helps Prevent Highs

Increases basal insulin dosing and delivers automatic correction boluses^† (up to one an hour) if sensor glucose is predicted to be high.

Helps Increase Time in Range

Settings for sleep and exercise activities use a narrower range of treatment values to adjust for activity variability.

Time In Range Improvements By Baseline Alc Graph

Control-IQ Technology:
The Great Equalizer

Control-IQ technology helps users achieve improvements in time in range irrespective of starting A1c or prior insulin regimen.³

See the Evidence

Professional Resources

Browse educational resources and product tips so users can make the most of their experience.

View Resources

Clinical Evidence

Clinical studies have demonstrated the safety, efficacy, and ease of use of Tandem automated insulin delivery.

See Studies

Industry Events

Explore live conferences, virtual events, and learning environments attended or hosted by Tandem.

Coming Soon

Responsible Use of Control‑IQ Technology

Even with advanced systems such as Control-IQ technology, users are still responsible for actively managing their diabetes. Control-IQ technology does not prevent all high and low blood glucose events. The system is designed to help reduce glucose variability, but it requires that users accurately input information, such as meals and periods of sleep or exercise. Control-IQ technology will not function as intended unless all system components, including CGM, infusion sets and pump cartridges, are used as instructed. Importantly, the system cannot adjust insulin dosing if the pump is not receiving CGM readings. Because there are situations and emergencies that the system may not be capable of identifying or addressing, users should always pay attention to their symptoms and treat accordingly.

* CGM sold separately.

† If glucose values are predicted to be above 10.0 mmol/L, Control-IQ technology calculates a correction bolus using the Personal Profile settings and a target of 6.1 mmol/L and delivers 60% of that value.

References

1. Breton MD, Kovatchev BP. One year real-world use of the Control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther. 2021;23(9):601-608. doi: 10.1089/dia.2021.0097.

2. Graham R, Mueller L, Manning M, et. al. Real-World Use of Control-IQ Technology is Associated with a Lower Rate of Severe Hypoglycemia and Diabetic Ketoacidosis than Historical Data: Results of the Control-IQ Observational (CLIO) Prospective Study. Diabetes Technol Ther. 2024;26(1):24-32. doi: 10.1089/ dia.2023.0341.

3. Beck RW, Kanapka LG, Breton MD, et al. A Meta-Analysis of Randomized Trial Outcomes for the t:slim X2 Insulin Pump with Control-IQ technology in Youth and Adults from Age 2 to 72. Diabetes Technol Ther. 2023;25(5):329-342. doi: 10.1089/dia.2022.0558.

This product may not be right for you. Always read and follow the label.

Important Safety Information

The t:slim X2 insulin pump with Control-IQ technology (the System) consists of the t:slim X2 insulin pump, which contains Control-IQ technology, and a compatible continuous glucose monitor (CGM, sold separately). The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in people requiring insulin. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and as part of the System. When used with a compatible CGM, the System can be used to automatically increase, decrease, and suspend delivery of basal insulin based on CGM sensor readings and predicted glucose values. The System can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. The pump and the System are indicated for use in individuals 6 years of age and greater. The pump and the System are intended for single user use. The pump and the System are indicated for use with NovoRapid, Admelog, Trurapi, or Humalog U-100 insulin. The System is intended for the management of Type 1 diabetes.

Warning: Control-IQ technology should not be used by anyone under the age of 6 years old. It should also not be used in users who require less than 10 units of insulin per day or who weigh less than 25 kilograms.

The System is not indicated for use in pregnant women, people on dialysis, or critically ill users. Do not use the System if using hydroxyurea.

Users of the pump and the System must: be willing and able to use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient diabetes self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The t:slim X2 pump must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information.

The Tandem Source platform is intended for use by individuals with diabetes mellitus who use Tandem Diabetes Care insulin pumps, their caregivers, and their healthcare providers in home and clinical settings. The Tandem Source platform supports diabetes management through the display and analysis of information uploaded from Tandem insulin pumps.

t:slim X2 Insulin Pump #1 Prescribed Insulin Pump in Canada

Immediate Improvements

Decrease in Burden

More Control Overnight

t:slim X2 Insulin Pump

Helps Prevent Lows

Helps Prevent Highs

Helps Increase Time in Range

Control-IQ Technology:
The Great Equalizer

Tandem Source Intuitive Reporting

Professional Resources

Clinical Evidence

Industry Events

Software

Information

Disclosures

t:slim X2 Insulin Pump #1 Prescribed Insulin Pump in Canada

Immediate Improvements

Decrease in Burden

More Control Overnight

t:slim X2 Insulin Pump

Helps Prevent Lows

Helps Prevent Highs

Helps Increase Time in Range

Control-IQ Technology: The Great Equalizer

Tandem Source Intuitive Reporting

Professional Resources

Clinical Evidence

Industry Events

Control-IQ Technology:
The Great Equalizer